Qing Li

Dr. Qing Li


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JZJun Zhu
Jun Zhu
LYLibo Yao
Libo Yao
LCLing Chau
Ling Chau
SNSamuel Sai‐Ming Ng
Samuel Sai‐Ming Ng
YPYing Peng
Ying Peng
MLMarie Chia‐Mi Lin
Marie Chia‐Mi Lin
The most severe form of brain glioma, glioblastoma (GBM), is highly malignant and usually resistant to chemotherapy. Therefore, discovery of new targets for gene therapy is important. Using subtraction cloning, we identified the human N‐Myc downstream‐regulated gene 2 (hNDRG2), located at chromosome 14q11.2, as a gene that is significantly suppressed in GBM tissues. Semiquantitative RT‐PCR showed that the hNDRG2 gene transcript is expressed in normal brain tissue and low‐grade gliomas but is present at low levels in 15 of 27 (56%) human GBM tissues and all of the 6 human glioblastoma cell lines examined. Furthermore, transfection of human glioblastoma U373 and U138 cells with a cDNA encoding hNDRG2 markedly reduced the cell proliferation. Our findings provide the first evidence to suggest that hNDRG2 may play a role in glioblastoma carcinogenesis.

27 November 2013 in Nature
Verified
Journal Article
Open access
PDF file
QLQing Li
Qing Li
NBNatacha Bohin
Natacha Bohin
TWTiffany Wen
Tiffany Wen
VNVictor Ng
Victor Ng
JMJeffrey Magee
Jeffrey Magee
SMSean J. Morrison
Sean J. Morrison
Oncogenic Nras in mouse haematopoietic stem cells can increase the probability of cell division in some cells and decrease it in others; this bimodal activity explains how this single pre-leukaemic mutation can increase proliferation without reducing competitiveness by clonally expanding the rapidly dividing cell population and also promoting long-term self-renewal of stem cells. The Nras oncogene is often mutated at an early stage in the development of some forms of myeloproliferative disease and leukaemia. Sean Morrison and colleagues now show in a mouse model that activation of Nras in haematopoietic stem cells exerts a bimodal effect, increasing the likelihood of cell division in some, but decreasing it in other cells. This allows this single pre-leukaemic mutation to clonally expand the more rapidly dividing cell population, yet also to promote long-term self-renewal in the more slowly dividing cells. The authors suggest that by shepherding its resources in this way, Nras-mutated cells can outcompete wild-type rivals and increase the chance of acquiring further mutations and at the same time sustain long-term clonal dominance. ‘Pre-leukaemic’ mutations are thought to promote clonal expansion of haematopoietic stem cells (HSCs) by increasing self-renewal and competitiveness1; however, mutations that increase HSC proliferation tend to reduce competitiveness and self-renewal potential, raising the question of how a mutant HSC can sustainably outcompete wild-type HSCs. Activating mutations in NRAS are prevalent in human myeloproliferative neoplasms and leukaemia2. Here we show that a single allele of oncogenic NrasG12D increases HSC proliferation but also increases reconstituting and self-renewal potential upon serial transplantation in irradiated mice, all prior to leukaemia initiation. NrasG12D also confers long-term self-renewal potential to multipotent progenitors. To explore the mechanism by which NrasG12D promotes HSC proliferation and self-renewal, we assessed cell-cycle kinetics using H2B–GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation. NrasG12D had a bimodal effect on HSCs, increasing the frequency with which some HSCs divide and reducing the frequency with which others divide. This mirrored bimodal effects on reconstituting potential, as rarely dividing NrasG12D HSCs outcompeted wild-type HSCs, whereas frequently dividing NrasG12D HSCs did not. NrasG12D caused these effects by promoting STAT5 signalling, inducing different transcriptional responses in different subsets of HSCs. One signal can therefore increase HSC proliferation, competitiveness and self-renewal through bimodal effects on HSC gene expression, cycling and reconstituting potential.

18 December 2014 in Blood
Verified
Journal Article
Open access
PDF file
MBMichael R. Burgess
Michael R. Burgess
EHEugene Hwang
Eugene Hwang
AFAri J. Firestone
Ari J. Firestone
THTannie Huang
Tannie Huang
JXJin Xu
Jin Xu
QLQing Li
Qing Li
Key Points: N-Ras expression is essential for the proliferative advantage of acute myeloid leukemias with oncogenic NRAS/Nras mutations. Mitogen-activated protein kinase kinase inhibition prolongs survival in Nras-mutant AML by reducing proliferation, but fails to undergo apoptosis.

18 February 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LLLu Liu
Lu Liu
MZMeiling Zhao
Meiling Zhao
XJXi Jin
Xi Jin
GNGina Ney
Gina Ney
KYKevin B Yang
Kevin B Yang
QLQing Li
Qing Li

24 December 2020 in Blood
Verified
Journal Article
Open access
PDF file
LLLu Liu
Lu Liu
AIAyaka Inoki
Ayaka Inoki
KFKelly Fan
Kelly Fan
FMFengbiao Mao
Fengbiao Mao
GSGuojun Shi
Guojun Shi
QLQing Li
Qing Li
Hematopoietic stem cells (HSC) self-renew to sustain stem cell pools and differentiate to generate all types of blood cells. HSCs remain in quiescence to sustain their long-term self-renewal potential. It remains unclear whether protein quality control is required for stem cells in quiescence when RNA content, protein synthesis, and metabolic activities are profoundly reduced. Here, we report that protein quality control via endoplasmic reticulum-associated degradation (ERAD) governs the function of quiescent HSCs. The Sel1L/Hrd1 ERAD genes are enriched in the quiescent and inactive HSCs, and conditional knockout of Sel1L in hematopoietic tissues drives HSCs to hyperproliferation, which leads to complete loss of HSC self-renewal and HSC depletion. Mechanistically, ERAD deficiency via Sel1L knockout leads to activation of mammalian target of rapamycin (mTOR) signaling. Furthermore, we identify Ras homolog enriched in brain (Rheb), an activator of mTOR, as a novel protein substrate of Sel1L/Hrd1 ERAD, which accumulates upon Sel1L deletion and HSC activation. Importantly, inhibition of mTOR, or Rheb, rescues HSC defects in Sel1L knockout mice. Protein quality control via ERAD is, therefore, a critical checkpoint that governs HSC quiescence and self-renewal by Rheb-mediated restriction of mTOR activity.

16 February 2018 in eLife
Verified
Journal Article
Open access
RCRichard H Chapple
Richard H Chapple
THTianyuan Hu
Tianyuan Hu
YTYu-Jung Tseng
Yu-Jung Tseng
LLLu Liu
Lu Liu
AKAyumi Kitano
Ayumi Kitano
DNDaisuke Nakada
Daisuke Nakada
Activation of the unfolded protein response (UPR) sustains protein homeostasis (proteostasis) and plays a fundamental role in tissue maintenance and longevity of organisms. Long-range control of UPR activation has been demonstrated in invertebrates, but such mechanisms in mammals remain elusive. Here, we show that the female sex hormone estrogen regulates the UPR in hematopoietic stem cells (HSCs). Estrogen treatment increases the capacity of HSCs to regenerate the hematopoietic system upon transplantation and accelerates regeneration after irradiation. We found that estrogen signals through estrogen receptor α (ERα) expressed in hematopoietic cells to activate the protective Ire1α-Xbp1 branch of the UPR. Further, ERα-mediated activation of the Ire1α-Xbp1 pathway confers HSCs with resistance against proteotoxic stress and promotes regeneration. Our findings reveal a systemic mechanism through which HSC function is augmented for hematopoietic regeneration.